Research programme: aurora kinase inhibitors - Chroma Therapeutics

Drug Profile

Research programme: aurora kinase inhibitors - Chroma Therapeutics

Alternative Names: CCT-129202; Multi-kinase inhibitors - Chroma Therapeutics

Latest Information Update: 15 May 2008

Price : $50

At a glance

  • Originator Chroma Therapeutics
  • Class Small molecules
  • Mechanism of Action Aurora kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 15 May 2008 Preclinical development is ongoing
  • 09 Mar 2005 Preclinical trials in Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top